CurrentBlue Shield of CaliforniaPolicy 7.01.121

Saturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer

Customize your policy alerts

Sign up for blue_shield_of_california Policy 7.01.121 alerts

Get alerted when Policy 7.01.121 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs the coverage status of saturation biopsy when used for the diagnosis, staging, or management of prostate cancer. Blue Shield of California considers saturation biopsy investigational for these uses.

Policy Summary

PayerBlue Shield of California

PolicySaturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer

Policy CodePolicy N/A

Change TypeAdministrative and evidence-review updateno material clinical or coverage change

Effective DateOctober 1, 2026

Next Review DateN/A

Key ActionTreat saturation biopsy as investigational for the diagnosis, staging, or management of prostate cancer.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

InvestigationalCoverage status of saturation biopsy

3 usesProstate cancer care contexts addressed

>20 coresGeneral saturation biopsy definition

NoneDirect evidence for management or health outcomes

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentBlue Shield of CaliforniaPolicy 7.01.121

Saturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer

Customize your policy alerts

Sign up for blue_shield_of_california Policy 7.01.121 alerts

Get alerted when Policy 7.01.121 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerBlue Shield of California

PolicySaturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer

Policy CodePolicy N/A

Change TypeAdministrative and evidence-review updateno material clinical or coverage change

Effective DateOctober 1, 2026

Next Review DateN/A

Key ActionTreat saturation biopsy as investigational for the diagnosis, staging, or management of prostate cancer.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

InvestigationalCoverage status of saturation biopsy

3 usesProstate cancer care contexts addressed

>20 coresGeneral saturation biopsy definition

NoneDirect evidence for management or health outcomes

10/01/2026Most recent annual review

Coverage Criteria

Diagnosis, Staging, or Management

Considered investigational when used for any of the following purposes:

Any of the following uses

Diagnosis: Use for diagnosis of prostate cancer.
Staging: Use for staging of prostate cancer.
Management: Use for management of prostate cancer.

Active Surveillance Evidence

For active surveillance, available evidence does not establish clinical utility for saturation biopsy over standard biopsy.

Insufficient evidence for clinical utility: No direct evidence was identified comparing saturation biopsy with standard biopsy for patient management decisions or health outcomes, and evidence was insufficient to demonstrate improved identification of tumor grade.

Observational studies found no significant differences in upstaging or identification of high Gleason score.

Repeat Biopsy Guidance

For patients with previous negative biopsies, saturation biopsy is not recommended as a routine strategy.

Routine use after previous negative biopsy: NCCN does not recommend a saturation biopsy strategy for all individuals with previous negative biopsies despite emerging evidence.

Most physician reviewers considered saturation biopsy investigational in patients with two prior negative biopsies and persistently rising prostate-specific antigen levels.

Saturation Biopsy for Prostate Cancer

Investigational status: Saturation biopsy is considered investigational in the diagnosis, staging, and management of prostate cancer.

Saturation biopsy is considered investigational when used for the diagnosis, staging, or management of prostate cancer.

Most physician reviewers stated that saturation biopsy is investigational and did not consider it medically necessary for patients with two prior negative biopsies and persistently rising prostate-specific antigen levels.

Coding and Procedure Details

CPTCPT

55706

Biopsies, prostate, needle, transperineal, stereotactic template guided saturation sampling, including imaging guidance Ultrasonic guidance for needle placement (e.g., biopsy, aspiration,.

HCPCSHCPCS

G0416

injection, localization device), imaging supervision and interpretation Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method

Number of prostate biopsy cores

General thresholdMore than 20 biopsy tissue cores

Alternative thresholdOccasionally defined as more than 18 biopsy tissue cores

Sampling methodSystematic sampling from the prostate

Saturation biopsy core count

Typical saturation biopsyMore than 20 tissue cores

Occasional definitionMore than 18 tissue cores

Procedure type

Provider Actions and Review Considerations

Documentation Required

No clinical review records required

No records are required for clinical review.

Denial Risk

Investigational status may lead to denial

Saturation biopsy is considered investigational when used for the diagnosis, staging, or management of prostate cancer, creating a risk of noncoverage or denial under the policy.

Diagnosis of prostate cancer
Staging of prostate cancer
Management of prostate cancer

Background

Saturation biopsy is a systematic prostate biopsy that samples substantially more tissue than a standard biopsy, generally involving more than 20 cores and occasionally defined as more than 18 cores. It may be performed using a transrectal or transperineal approach and has been proposed for initial or repeat diagnosis, staging, and management of prostate cancer, including selection of patients for active surveillance.

Definitions

Saturation biopsy

ProcedureSystematic prostate biopsy

Typical samplingGenerally more than 20 biopsy tissue cores

Alternative definitionOccasionally more than 18 biopsy tissue cores

Saturation biopsy

DefinitionA systematic biopsy obtaining more than 20 biopsy tissue cores from the prostate

Occasional definitionMore than 18 biopsy tissue cores

ApproachesMay be performed transrectally or transperineally

Policy Summary

PayerBlue Shield of California

PolicySaturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer

Policy CodePolicy N/A

Change TypeAdministrative and evidence-review updateno material clinical or coverage change

Effective DateOctober 1, 2026

Next Review DateN/A

Key ActionTreat saturation biopsy as investigational for the diagnosis, staging, or management of prostate cancer.

SourceLink

On This Page

Systematic prostate biopsy

Active surveillance candidate criteria

Gleason scoreNo greater than 6

Clinical stageT1 or T2a

PSA levelLess than 10 ng/mL

Core involvementNo more than 33% of cores

High Gleason grade

High Gleason grade thresholdGleason grade ≥4

Active surveillance contextPatients with Gleason scores of 4 or higher were generally not considered candidates for active surveillance

Assessment comparisonNo statistically significant differences were found between 12-core and saturation biopsies for detecting high Gleason grade

Avoid routine repeat saturation biopsy

Saturation biopsy may be considered investigational or unsupported after two prior negative biopsies with persistently rising prostate-specific antigen levels. NCCN does not recommend a saturation biopsy strategy for all individuals with previous negative biopsies.

Clinically valid

Condition detectionDetects the presence or absence of a condition

Future riskDetects the risk of developing a condition in the future

Treatment responseDetects treatment response, whether beneficial or adverse

Clinically useful

Core definitionResults inform management decisions that improve the net health outcome of care

Appropriate treatmentMay enable patients to receive correct or more effective therapy

Avoidance of unnecessary careMay help avoid unnecessary therapy or testing

Direct evidence

Evidence sourceStudies comparing health outcomes for patients managed with and without the test

Preferred designRandomized controlled trials are preferred

PurposeProvides evidence of clinical utility

Chain of evidence

Evidence typeIndirect evidence of clinical utility based on clinical validity

Required foundationEvidence must demonstrate test performance

LimitationIf test performance is insufficiently demonstrated, clinical utility cannot be inferred

Saturation biopsy

ProcedureSystematic prostate biopsy

General core countMore than 20 tissue cores

Occasional core countMore than 18 cores

Clinically useful

Clinical utilityTest results inform management decisions that improve the net health outcome of care

Potential benefitPatients may receive correct or more effective therapy

Potential avoidancePatients may avoid unnecessary therapy or testing

Active surveillance

Management approachManagement of selected individuals with prostate cancer

Key assessmentAccurate Gleason score assessment is important

Selection purposeDetermines whether the patient is sufficiently low risk for surveillance

Clinically useful

DefinitionA test is clinically useful when results inform management decisions that improve net health outcomes

Treatment impactResults may enable correct or more effective therapy

Testing impactResults may help avoid unnecessary therapy or testing

Direct evidence

Evidence sourceStudies comparing health outcomes for patients managed with and without the test

Preferred evidenceRandomized controlled trials are preferred because they are intervention studies

Active surveillance findingNo direct evidence was identified comparing saturation biopsy with standard biopsy for management decisions or health outcomes

Chain of evidence

Evidence typeIndirect evidence of clinical utility rests on clinical validity

Performance requirementEvidence must demonstrate test performance

Inference limitationWhen evidence is insufficient to demonstrate test performance, no inference about clinical utility can be made